Issue release date: 12.11.2024
2Yeditepe University, School of Genetics and Bioengineering, Istanbul, Turkey
3Istanbul Medeniyet University, Goztepe Training and Research Hospital, Department of Neurosurgery, Istanbul, Turkey
4Medipol University, School of Medicine Hospital, Department of Neurosurgery, Istanbul, Turkey DOI : 10.5137/1019-5149.JTN.9823-13.1 AIM: The matrix metalloproteinase (MMP) enzyme family has been shown to be active in tumorigenesis and tumor progression. In this study, we analyzed the prevalence of a guanine insertion in the MMP-1 gene promoter region in meningiomas and its effect on invasion and prognosis.
MATERIAL and METHODS: The study was performed with 33 meningioma patients. We also included 33 healthy patients in the study as a control group. The promoter area was amplified by polymerase chain reaction (PCR) following DNA isolation. The polymorphism was detected by restriction fragment length polymorphism (RFLP).
RESULTS: According to the WHO classification of meningiomas, 87.9% of the affected patients were grade 1, and 12.1% were grade 2. In total, 72.7% of the meningioma patients (n=24) had at least one copy of the insertion (2G/1G or 2G/2G genotypes) and 27.3% (n=9) did not (1G/1G). There was no significant difference between the meningioma and control groups according to genotype distribution.
CONCLUSION: In this study, the polymorphism in the matrix metalloproteinase-1 gene promoter region did not have an effect on the initiation, growth and progression of meningioma.
Keywords : Meningioma, Single nucleotide polymorphism, SNP, MMP-1, Interstitial collagenase, Matrix metalloproteinase